Closing Bell: Amylyx Pharmaceuticals Climbs, Targa Rises, Klarna Plunges

Today's biggest winners and losers in the stock market.
On this episode of Stock Movers:

Listen for comprehensive cross-platform coverage of the US market close as heard on Bloomberg Television, Bloomberg Radio, and YouTube with Scarlet Fu, Isabelle Lee, Carol Massar and Joe Deaux

- Amylyx Pharmaceuticals (AMLX) shares climb as much as 43%, the most intraday since September 2022, after the drug developer said a late-stage trial of its experimental drug met its primary endpoint as a treatment for patients who experience dangerously low blood sugar levels following bariatric surgery. Stifel views the results as a “best-case scenario.”

- Targa Resources (TRGP) shares rose 6.9% after the energy company signed new 20-year, fee-based integrated midstream agreements with ExxonMobil subsidiaries covering gathering, processing, NGL transportation, and fractionation across the Permian Basin through 2046.

- Klarna (KLAR) shares are down more than 20% after the payments company reported full year revenue and gross merchandise value guidance that missed expectations. Active consumers for the second quarter also missed expectations.

See omnystudio.com/listener for privacy information.